4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Primary adenocarcinoma of the urinary bladder: value of cell cycle biomarkers.

      American journal of clinical pathology
      Adenocarcinoma, metabolism, mortality, pathology, Adult, Aged, Cohort Studies, Cyclin E, Cyclin-Dependent Kinase Inhibitor p21, Cystectomy, Female, Humans, Immunohistochemistry, methods, Kaplan-Meier Estimate, Ki-67 Antigen, Lymph Nodes, Male, Microarray Analysis, Middle Aged, Neoplasm Recurrence, Local, Proliferating Cell Nuclear Antigen, Staining and Labeling, Tumor Markers, Biological, Tumor Suppressor Protein p53, Urinary Bladder Neoplasms, surgery

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Primary adenocarcinomas of the urinary bladder are uncommon, and the molecular pathways are currently not well defined. In this study, we assessed the association between biologic markers and clinicopathologic characteristics in a cohort of 21 patients with primary urinary bladder adenocarcinoma. Immunohistochemical staining for cell cycle-specific markers, including p53, p21, p27, Ki-67, and cyclin E, were performed on sections of a tissue microarray construct. The tumors were high grade in 12 (57%) and pT2 or higher in 18 (86%); lymph nodes were involved in 6 cases (29%); and there was pathologic evidence of schistosomiasis in 14 (67%). The best prognostic combination of markers was combined alterations in p27 and Ki-67 and was associated with stage (P = .012), grade (P = .005), DNA ploidy (P = .005), and lymph node involvement (P = .04). Stage, lymph node involvement, combined alterations of p27 and Ki-67, and combined alterations of all 5 biomarkers were associated with increased probability of disease recurrence and cancer-specific mortality (P < .05).

          Related collections

          Author and article information

          Comments

          Comment on this article